June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Rates and Features of Neovascularization Associated with Successful Intravenous Chemotherapy Treatment of Retinoblastoma
Author Affiliations & Notes
  • Kai B. Kang
    Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, Chicago, IL
  • Michael Shapiro
    Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, Chicago, IL
  • Michael P. Blair
    Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, Chicago, IL
  • Felix Yan-Fay Chau
    Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, Chicago, IL
  • Footnotes
    Commercial Relationships Kai Kang, None; Michael Shapiro, None; Michael Blair, None; Felix Chau, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 86. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kai B. Kang, Michael Shapiro, Michael P. Blair, Felix Yan-Fay Chau; Rates and Features of Neovascularization Associated with Successful Intravenous Chemotherapy Treatment of Retinoblastoma. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):86.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

Retinoblastoma (RB) treatments include enucleation, radiotherapy, cryotherapy, laser photocoagulation and chemotherapy. Certain features of RB may be safely monitored without further treatment. The purpose of this study is to evaluate rates and describe features of retinal neovascularization associated with successful intravenous chemotherapy and focal consolidation of tumors with laser or cryotherapy.

 
Methods
 

Retrospective review of digital fundus images and medical records of RB patients who presented to the University of Illinois at Chicago, Illinois Eye and Ear Infirmary Retina Clinic from November 1, 2004 to November 1, 2014. Only surviving eyes that received treatment for RB with a minimum length of follow up of one year were included.

 
Results
 

50 eyes of 34 patients received treatment over the study period. 18 patients had unilateral RB, and 16 had bilateral RB. The mean age at diagnosis was 16 months. Of the 50 eyes, 22 were enucleated upon diagnosis. Most (86%) of the enucleated eyes were classified as International Classification of Retinoblastoma (ICRB) Group E. Twenty-five eyes received intravenous chemotherapy consisting of six cycles of carboplatin, etoposide and vincristine as the primary treatment. Twenty-two (88%) eyes (with 2 in ICRB group A, 6 in Group B, 10 in Group C and 4 in Group D) showed no tumor progression over the study period. Neovascularization was identified in 3 eyes (14% of 22 eyes) in 3 patients. These eyes were monitored closely without further treatment. The three eyes showed no tumor growth over respective periods of 9.1 years, 3.2 years, and 1.2 years. All 3 were associated with calcified regression, and 2 with preretinal fibrosis and subretinal fluid (one with inferior detachment successfully treated with scleral buckle).

 
Conclusions
 

The rate of retinal neovascularization in eyes with successful intravenous chemotherapy was approximately 14%. Neovascularization associated with retinoblastoma may be safely monitored without the need for further treatment if there are no signs of tumor progression.  

 
A) Fundus photos illustrating regressed tumor with calcified remnants after chemotherapy and laser with neovascularization and fibrosis from 2005 to 2009
 
A) Fundus photos illustrating regressed tumor with calcified remnants after chemotherapy and laser with neovascularization and fibrosis from 2005 to 2009
 
 
B) Fundus photographs of the same eye illustrating continued neovascularization with fibrosis and adjacent calcified remnants without further tumor growth from 2011 to 2014
 
B) Fundus photographs of the same eye illustrating continued neovascularization with fibrosis and adjacent calcified remnants without further tumor growth from 2011 to 2014

 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×